Grace Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr '26 Apr 10, 2026	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021
Market Cap	56	31	-	-	-	-
Market Cap Growth	113.66%	-	-	-	-	-
Enterprise Value	37.34	9.14	0	0	0	0
Last Close Price	3.59	2.28	-	-	-	-
PE Ratio	-	-2.89	-	-	-	-
PB Ratio	0.86	0.47	-	-	-	-
P/TBV Ratio	0.87	0.41	-	-	-	-
P/FCF Ratio	-	-2.10	-	-	-	-
P/OCF Ratio	-	-2.10	-	-	-	-
EV/EBITDA Ratio	-	-0.55	-	-	-	-
EV/EBIT Ratio	-	-0.55	-	-	-	-
EV/FCF Ratio	-	-0.61	-	-	-	-
Debt / Equity Ratio	-	0	0	0.01	0.00	0
Debt / EBITDA Ratio	-	-	-	-0.01	-0.02	-0.01
Debt / FCF Ratio	-	-	-	-0.03	-0.02	-0.01
Net Debt / Equity Ratio	-0.29	-0.33	-0.37	-0.40	-0.40	-1.09
Net Debt / EBITDA Ratio	1.66	1.33	1.79	0.53	2.78	3.91
Net Debt / FCF Ratio	1.84	1.49	1.86	1.72	2.52	4.22
Quick Ratio	14.56	11.53	14.09	8.41	13.56	38.80
Current Ratio	14.96	11.77	14.26	8.59	13.89	39.50
Return on Equity (ROE)	-10.22%	-14.91%	-19.82%	-48.15%	-18.23%	-57.33%
Return on Assets (ROA)	-14.82%	-17.21%	-14.76%	-40.99%	-15.64%	-38.49%
Return on Invested Capital (ROIC)	-19.88%	-25.90%	-23.31%	-65.66%	-36.43%	-2149.08%
Return on Capital Employed (ROCE)	-17.79%	-23.54%	-17.45%	-51.88%	-16.74%	-43.02%
Earnings Yield	-10.67%	-34.65%	-	-	-	-
FCF Yield	-18.08%	-47.65%	-	-	-	-
Buyback Yield / Dilution	-36.09%	-26.85%	-28.16%	-21.09%	-148.46%	-40.25%
Total Shareholder Return	-36.09%	-26.85%	-28.16%	-21.09%	-148.46%	-40.25%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q